Commentary: Citicoline: A Food Beneficial for Patients Suffering from or Threated with Glaucoma by Vincenzo Parisi et al.
GENERAL COMMENTARY
published: 17 August 2016
doi: 10.3389/fnagi.2016.00194
Frontiers in Aging Neuroscience | www.frontiersin.org 1 August 2016 | Volume 8 | Article 194
Edited by:
Catarina Oliveira,
University of Coimbra, Portugal
Reviewed by:
Pawan Gupta,
University of Illinois at Chicago, USA
Rubem C. A. Guedes,
Federal University of Pernambuco,
Brazil
Neel Kamal Sharma,
National Eye Institute, USA
Nevena Divac,








Received: 13 May 2016
Accepted: 29 July 2016
Published: 17 August 2016
Citation:
Parisi V, Ziccardi L, Roberti G, Tanga L
and Manni G (2016) Commentary:
Citicoline: A Food Beneficial for
Patients Suffering from or Threated
with Glaucoma.
Front. Aging Neurosci. 8:194.
doi: 10.3389/fnagi.2016.00194
Commentary: Citicoline: A Food
Beneficial for Patients Suffering from
or Threated with Glaucoma
Vincenzo Parisi 1, Lucia Ziccardi 1*, Gloria Roberti 1, Lucia Tanga 1 and Gianluca Manni 2
1 “G.B. Bietti” Foundation for Study and Research in Ophthalmology—IRCCS, Rome, Italy, 2Department of Clinical Sciences
and Translational Medicine, University of Rome Tor Vergata, Rome, Italy
Keywords: citicoline, benzalkonium compounds, neuroprotection, glaucoma, eye
A commentary on
Citicoline: A Food Beneficial for Patients Suffering from or Threated with Glaucoma
by Grieb, P., Jünemann, A., Rekas, M., and Rejdak, R. (2016). Front. Aging Neurosci. 8:73. doi:
10.3389/fnagi.2016.00073
Dear Editor, we read with particular interest the complete review by Grieb et al. (2016).
About the paragraph “Citicoline for Glaucoma: Clinical Evidence,” we are not in agreement with
the Authors’ statement “The idea of topical delivery of Citicoline may not be endorsed.”
First, Grieb et al. (2016) stated that “Citicoline is water soluble and will poorly penetrate cornea.”
On this topic, we recently published (Roberti et al., 2014) a study with the aim to evaluate the ability
of Citicoline eye drops to reach the vitreous. The experiment was performed on five CD1 mice
divided in three groups. The right eye of two mice in the Group A were treated with a solution of
1%Citicoline, 0.2% highmolecular weight hyaluronic acid (HA), and 0.01% benzalkonium chloride
(BAK) while the right eye of two mice in the Group B were treated with a solution of 2% Citicoline,
0.2% HA, and 0.01% BAK (OMK1 R©, Omikron Italia s.r.l, Italy) and one mouse in the Group C was
used as control. Two drops twice-a-day for 3 days were administered. On the fourth day, after
sacrificing the animal, the eyes were taken, rinsed in saline, and stored in ice. After aspirating
the vitreous with a SGE Analytical Science 100 µL syringe, it was diluted with 20 µL of distilled
water. Then the vitreous was centrifuged and the 50 µL of solution 50% water and 50% methanol
were added to the collected supernatant and passed by vortex. For the sample analysis, liquid
chromatography and mass spectrometry (LC-MS/MS) was used. The instrumentation employed
consisted of triple-quadruple mass spectrometer (Applied Biosystems API 3000) equipped with a
turbo ion-spray and coupled to an UPLC (Dionex Ultimate 3000 RS). Once set all instrumental
and the analytical parameters to get the best conditions, the results were evaluated respect to the
therapeutic range expected. This was achieved by mean of a calibration curve built by deuterated
Citicoline standard solutions made at fixed concentrations. The vitreous was added with an equal
volume of water/methanol solution, containing deuterated-Citicoline. Then, the sample obtained
was processed though the LC-MS/MS system and between tests the machine had always done
white readings to avoid contamination. Interestingly, the machine detected the molecule very well
as the signal was present always at the same time and in all four transitions used. Therefore, we
concluded that the molecule reached the vitreous. We also noticed that there was a difference
between the concentrations 1 and 2% regarding the systemic absorption, which was zero for the
lower concentration.
Second, some criticism was posed by Grieb et al. (2016) about the use of BAK, since it may
“induce ocular surface changes and several other side effects.” In the cited work by Parisi et al.
(2015) it is clearly reported that “Throughout the entire period of treatment with topical Citicoline,
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and after the 2-month period of topical Citicoline wash-out, no
ocular adverse side effects were detected in any of the eyes that
concluded the study.” In particular, in our study we assessed,
as adverse side effects, the presence of conjunctival hyperemia,
corneal micro-abrasions, conjunctival, and corneal lesions, dry
eye, reduced quality, or quantity of tears and we performed
the Shirmer test in all patients. None of these ocular adverse
side effects have been detected in concomitance of Citicoline
eye drops treatment during a period of 4 months or later
during a period of 2 months of Citicoline eye drops wash-out.
Furthermore, the Shirmer test was unmodified for all the tested
patients at baseline and after treatment.
The lack of any observed adverse side effect, in relationship to
the cohort of our enrolled patients (patients under beta-blocker
monotherapy) may be ascribed to the following condition. The
eye drops contained Citicoline sodium salt: 0.2 g, HA: 0.02 g,
BAK 0.001 g, water for injection up to 10ml (OMK1 R©, Omikron
Italia, Italy). In the published review “Management and therapy
of dry eye disease: report of the Management and Therapy
Subcommittee of the International Dry Eye WorkShop (2007)”
it is clearly reported that “The toxicity of BAK is related to its
concentration, the frequency of dosing, the level or amount of
tear secretion, and the severity of the ocular surface disease. In
patients with mild dry eye, BAK-preserved drops are usually well
tolerated when used 4–6 times a day or less.” In our study, we
used BAK at the concentration of 0.01%, 3 times a day, that may
be considered a very low concentration that was not responsible
of any detected ocular surface changes in our previous studied
patients.
In addition, in order to reach a follow-up of at least
3 years, the study with topical Citicoline was actually
extended in the same patients enrolled in our previous
published work (Parisi et al., 2015). The entire functional
(electrophysiological and visual field) data will be available in
the January 2017. At this moment, all patients completed 30
months of follow-up and any patient treated with OMK1 R©,
showed none of the ocular adverse side effects mentioned
before.
Therefore, our works (Roberti et al., 2014; Parisi et al., 2015)
provide a sound evidence that (1) the Citicoline reaches the
vitreous in animal model; (2) there is a proof that Citicoline
may reach the vitreous and the retinal structures in patients
with glaucoma: this is derived by the effects of Citicoline eye
drops on the retinal increased function (neuroenhancement)
with consequent improvement of the neural conduction along
the visual pathways and related reduction of the mean defects
values (improvement of the visual field); (3) by using BAK as
vehicle for Citicoline eye drops at the concentration of 0.01%
any type of ocular surface changes were not detected during our
previous or actual (30 months) follow-up and thus the eye drops
are well tolerated. Thus, all this lead us to believe that Citicoline
eye drops can be endorsed in the management of glaucoma with
the possible aim to reduce the progression of visual glaucomatous
dysfunction.
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